Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Agios Opens Doors To Other Investors, Expands Into Genetic Disorders

This article was originally published in The Pink Sheet Daily

Executive Summary

Agios brings in a $78 million in financing from both previous venture investors and new public investor funds, as it embarks on research of rare diseases caused by an inborn error of metabolism.


Related Content

Agios Heads Toward Pivotal Study As FDA Places Hold On Backup
Deals Of The Week: Will Heated Competition To Buy Out Ache Laboratorios Muddy The Brazilian Waters?
Deals of the Week: Sanofi-Pasteur/CureVac, Shire/Shionogi, Genzyme/CFF, Medicis/Graceway
Celgene Expands Agios Collaboration In Cancer Metabolism
Genentech Licenses A Cancer Metabolism Program From Forma, With Option To Buy
Celgene Teams Up With Agios In Long-Term Cancer Metabolism Pact


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts